HAE

Haemonetics Corp Mass

• Simply Wall St·3h ago

  Haemonetics (HAE) Is Up 5.7% After FDA Expands VASCADE MVP XL Labeling for Larger EP Sheaths

• Simply Wall St·1d ago

  Is It Time To Reassess Haemonetics (HAE) After Recent Share Price Weakness?

• PR Newswire·04/01 20:05

  Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2026 Results: May 7, 2026

• TipRanks·03/31 10:36

  Haemonetics: FDA Label Expansion and New Product Launches Poised to Reignite Vascular Closure Growth by FY27

• Simply Wall St·03/30 23:06

  Is Haemonetics (HAE) Leveraging VASCADE MVP XL’s FDA Expansion To Deepen Its EP Moat?

• Benzinga·03/30 20:18

  Haemonetics Receives FDA Approval To Expand Labeling For VASCADE MVP XL Venous Vascular Closure System

• TipRanks·03/30 20:17

  Haemonetics: FDA approves expanded labeling for VASCADE MVP XL system

• PR Newswire·03/30 20:15

  Haemonetics Receives FDA Approval for Expanded Labeling of the VASCADE MVP® XL Venous Vascular Closure System

• Simply Wall St·03/26 21:08

  A Look At Haemonetics (HAE) Valuation After Recent Share Price Weakness

• NASDAQ·03/25 20:29

  Haemonetics Becomes Oversold (HAE)

• Simply Wall St·03/15 16:12

  Is Haemonetics (HAE) Quietly Rewiring Its Margin Profile Through NexSys PCS And Hospital Acquisitions?

• Simply Wall St·03/14 07:36

  Haemonetics Expands Hospital Portfolio As Investors Weigh Growth And Valuation

• Simply Wall St·03/12 22:36

  A Look At Haemonetics (HAE) Valuation After Recent Share Price Weakness

• Dow Jones·03/11 15:49

  Haemonetics Price Target Cut to $70.00/Share From $75.00 by Citigroup

• Dow Jones·03/11 15:49

  Haemonetics Is Maintained at Neutral by Citigroup